INFLUENZA, HUMAN

This study tested a new mRNA-based vaccine designed to protect against a potential H5 influenza (bird flu) pandemic. Nearly 1,000 healthy adults aged 18 to 85 received different doses to find the safest and most effective one. Researchers monitored side effects like pain, fever, …

This study tested whether new modified RNA (modRNA) flu vaccines are safe and help the body build protection against the flu. About 1,200 generally healthy adults aged 18 and older took part. Each person received one dose of either an experimental modRNA vaccine or a licensed flu…

This study tested a new type of flu vaccine called a self-amplifying RNA (saRNA) vaccine in 440 healthy adults aged 18 to 49. The goal was to see if it is safe and how the body responds compared to a licensed flu shot or a placebo. Participants received one injection and were fol…

This study tested whether a single injection combining a licensed COVID-19 vaccine and a licensed flu vaccine is safe and triggers a strong immune response. It involved 644 healthy adults aged 50 and older. The main goal was to check for side effects and measure antibody levels a…

This early-stage study tested a new type of seasonal flu vaccine called ARCT-2138, which uses self-amplifying mRNA technology to potentially provide stronger protection. Researchers gave the vaccine to 139 healthy adults aged 18-49 and 65-85 to check for side effects and measure …

This early-stage study tested a new mRNA-based flu vaccine from GSK in 324 healthy younger (18-45) and older (60-80) adults. The main goal was to see if the vaccine is safe and triggers an immune response. Researchers monitored side effects like pain, fever, and fatigue, and meas…

This study tested whether a booster vaccine for a bird flu strain (H5N6) is safe and boosts immunity in adults. About 260 people who had either a prior H5N1 vaccine or a placebo took part. Researchers measured antibody levels after one or two booster shots to see how well the bod…

This early-stage study tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against pandemic influenza in 212 healthy adults aged 18-80. Participants received either two doses of the experimental vaccine or one dose of a licensed flu vaccine plus a placebo. R…

This study tested a new quadrivalent (four-strain) flu vaccine made by Instituto Butantan in over 1,300 healthy infants and children aged 6 to 35 months. The goal was to see if the vaccine triggers a strong immune response and is safe compared to existing flu vaccines. Results wi…

This study tested a new mRNA-based seasonal flu vaccine from GSK in 845 healthy adults aged 18 to 85. The goal was to find the best dose and check how well it triggers the immune system and how safe it is. Results will help decide if the vaccine should move into larger trials.